← Leaderboards
Alice Stek
University Of Southern California
$1,651,428
Attributed
$1,651,428
Total exposure
19
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $474.5K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,651,428 · 19
By mechanism
M01$1,651,428 · 19
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Richard N Bergman$1,232,560
- Arshad M Khan$2,747,367
- Michael Lansdell Paine$20,118,574
- Thomas A Buchanan$121,360,154
- Jaimie Nicole Davis$4,966,715
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchFundingComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthGrantInstitutionResearch PersonnelSourceResourcesHuman SubjectWomanAids Education /PreventionHiv InfectionsZidovudineHuman Pregnant SubjectNevirapinePregnancyHuman Therapy EvaluationPharmacokineticsVertical TransmissionAntiretroviral TherapyDesignAdherence (Attribute)Embryo /Fetus Drug Adverse Effect
Grant awards (33)
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)$75,653
M01 · FY2009 · RR · contact PI
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)$56,737
M01 · FY2009 · RR · contact PI
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)$35,934
M01 · FY2008 · RR · contact PI
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)$23,218
M01 · FY2008 · RR · contact PI
A PHASE III, RANDOMIZED TRIAL OF THE SAFETY AND ANTIRETROVIRAL EFFECTS OF ZID$12,715
M01 · FY2008 · RR · contact PI
A PROSPECTIVE OBSERVATIONAL STUDY OF VIROLOGIC AND IMMUNLOGIC CHANGES IN HIV-$2,211
M01 · FY2008 · RR · contact PI
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS PROTEASE INHIBITOR-SPARING$2,211
M01 · FY2008 · RR · contact PI
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)$223,501
M01 · FY2007 · RR · contact PI
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)$144,414
M01 · FY2007 · RR · contact PI
A PHASE III, RANDOMIZED TRIAL OF THE SAFETY AND ANTIRETROVIRAL EFFECTS OF ZID$79,087
M01 · FY2007 · RR · contact PI
A PROSPECTIVE OBSERVATIONAL STUDY OF VIROLOGIC AND IMMUNLOGIC CHANGES IN HIV-$13,750
M01 · FY2007 · RR · contact PI
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS PROTEASE INHIBITOR-SPARING$13,750
M01 · FY2007 · RR · contact PI
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS PROTEASE INHIBITOR-SPARING$30,282
M01 · FY2006 · RR · contact PI
ASSESSMENT OF PREVALENCE AND PERSISTENCE OF HUMAN PAPILLOMA- VIRUS (HPV) DNA IN$6,060
M01 · FY2006 · RR · contact PI
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING VS PROTEASE INHIBITOR-SPARING$51,632
M01 · FY2005 · RR
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)$34,419
M01 · FY2005 · RR
EVALUATION OF METABOLIC COMPLICATIONS ASSOCIATED WITH ANTIRETROVIRAL MEDICATION$17,213
M01 · FY2005 · RR
ASSESSMENT OF PREVALENCE AND PERSISTENCE OF HUMAN PAPILLOMA- VIRUS (HPV) DNA IN$6,454
M01 · FY2005 · RR
RANDOMIZED TRIAL OF PROTEASE INHIBITOR-INCLUDING$178,440
M01 · FY2004 · RR
EVALUATION OF METABOLIC COMPLICATIONS$68,798
M01 · FY2004 · RR
PHASE I TRIAL OF SAFETY &PHARMACOKINETICS OF FORTOVASE$25,799
M01 · FY2004 · RR
ASSESSMENT OF PREVALENCE AND PERSISTENCE OF HPV DNA$6,450
M01 · FY2004 · RR
PERINATAL CORE PROTOCOL (PACTG P1025)$4,302
M01 · FY2004 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO FOR MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2002 · RR
POTENTIAL MUTAGENICITY OF ZDV &NUCLEOSIDE ANALOG IN PERINATAL HIV$0
M01 · FY2002 · RR
POTENTIAL MUTAGENICITY OF ZDV &NUCLEOSIDE ANALOG IN PERINATAL HIV$155,764
M01 · FY2001 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO FOR MATERNAL FETAL TRANSMISSION OF HIV$155,764
M01 · FY2001 · RR
POTENTIAL MUTAGENICITY OF ZDV &NUCLEOSIDE ANALOG IN PERINATAL HIV$0
M01 · FY2001 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO FOR MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2001 · RR
POTENTIAL MUTAGENICITY OF ZDV &NUCLEOSIDE ANALOG IN PERINATAL HIV$155,764
M01 · FY2000 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO FOR MATERNAL FETAL TRANSMISSION OF HIV$35,553
M01 · FY2000 · RR
POTENTIAL MUTAGENICITY OF ZDV &NUCLEOSIDE ANALOG IN PERINATAL HIV$35,553
M01 · FY2000 · RR
NEVIRAPINE VS NEVIRAPINE PLACEBO FOR MATERNAL FETAL TRANSMISSION OF HIV$0
M01 · FY2000 · RR